Platinum-Resistant Ovarian Cancer: Bevacizumab Improves Survival When Added to Chemotherapy

VBCC - November 2012, Volume 3, No 8 - ESMO 2012 Conference
Phoebe Starr

Vienna, Austria—Adding bevacizumab (Avastin) to chemotherapy im­proves outcomes in patients with platinum-resistant recurrent ovarian cancer, according to results of the phase 3 clinical trial AURELIA, which was presented at the 2012 European Society for Medical Oncology Congress. Bevacizumab im­proved progression-free survival (PFS) and overall response rate (ORR) with any of the 3 chemotherapy regimens in the study, but adding bevacizumab to weekly paclitaxel was the most active combination in an exploratory analysis of the trial.

AURELIA is one of the only trials to show a positive outcome in patients with platinum-resistant ovarian cancer, said Nicoletta Colombo, MD, University of Milan-Bicocca, European Institute of Oncology, Milan, Italy.

In the overall trial, the median PFS was 6.7 months for bevacizumab plus chemotherapy versus 3 months for chemotherapy alone.

Investigators could choose chemotherapy from among weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan. When chemotherapy regimens were analyzed separately, the bevacizumab plus weekly paclitaxel regimen achieved the best results. The median PFS durations for the different cohorts were:

  • 10.4 months with bevacizumab plus weekly paclitaxel versus 3.9 months with chemotherapy alone
  • 5.8 months with bevacizumab plus topotecan versus 2.1 months with chemotherapy alone
  • 5.4 months with bevacizumab plus pegylated liposomal doxorubicin versus 3.4 months with chemotherapy alone.

“Bevacizumab combined with chemotherapy should be considered a new standard option for platinum-resistant recurrent ovarian cancer,” stated lead author Andres M. Poveda, MD, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain.

AURELIA randomized 361 patients (median age, approximately 60 years) with platinum-resistant recurrent ovarian cancer whose disease progressed with up to 2 previous regimens to chemotherapy alone versus chemotherapy plus bevacizumab. Treatment was continued until unacceptable toxicity or progressive disease occurred.

Demographic and disease charac­teristics were well balanced at base­line between the treatment arms. Approximately 90% of the patients had stage III/IV disease.

Response rates were superior for all 3 chemotherapy regimens with the addition of bevacizumab, with the highest rate seen with weekly paclitaxel plus bevacizumab—51.7% versus 28.8% for chemotherapy alone; the ORRs for bevacizumab plus pegylated liposomal doxorubicin were 18.3% and 7.9%, respectively, and 5.8% and 2.1%, respectively, for the topotecan cohort.

No new toxicity concerns emerged in the trial. Toxicities were similar in the 2 treatment arms. A higher rate of peripheral neuropathy was reported in the weekly paclitaxel cohort and a higher rate of hand-foot syndrome in the patients treated with pegylated liposomal doxorubicin.

Dr Colombo was particularly im­pressed by the results in the weekly paclitaxel plus bevacizumab cohort. She stated that this combination should be explored earlier in the course of disease.

Related Items
Tocilizumab Demonstrates Success in the Treatment of Patients with Giant Cell Arteritis
Phoebe Starr
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Giant Cell Arteritis
Rituximab Maintenance Outshines Azathioprine for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Phoebe Starr
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Vasculitis
Cost of Drugs and Affordability Don’t Always Jibe
Phoebe Starr
VBCC - July 2016, Vol 7, No 6 published on July 13, 2016 in Value in Oncology
Usefulness of Vitamin D Supplementation Questioned in Patients with Knee Osteoarthritis
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Osteoarthritis
Baricitinib Effective in Patients with Refractory Rheumatoid Arthritis
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Rheumatoid Arthritis
Vaccine Uptake Remains Low in Patients with RA
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Health & Wellness
Age, Smoking History Are Risk Factors for Early Organ Damage in Patients with SLE
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Lupus
IL-6 Inhibitor Shows Promise in Patients with PsA
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Psoriatic Arthritis
ESR1 Mutations Predict Worse Survival in ER-Positive Advanced Breast Cancer
Phoebe Starr
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Personalized Medicine
Early Results of Immunotherapy in Breast Cancer
Phoebe Starr
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Breast Cancer
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology